254 related articles for article (PubMed ID: 12752145)
1. Infliximab for peristomal pyoderma gangrenosum.
Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
[TBL] [Abstract][Full Text] [Related]
2. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
3. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease.
Batres LA; Mamula P; Baldassano RN
J Pediatr Gastroenterol Nutr; 2002 May; 34(5):558-60. PubMed ID: 12050585
[No Abstract] [Full Text] [Related]
4. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
Cocco A; Angelucci E; Viscido A; Caprilli R
Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
[No Abstract] [Full Text] [Related]
5. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
6. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
7. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
8. Dermatologic manifestations of Crohn disease in children: response to infliximab.
Kugathasan S; Miranda A; Nocton J; Drolet BA; Raasch C; Binion DG
J Pediatr Gastroenterol Nutr; 2003 Aug; 37(2):150-4. PubMed ID: 12883301
[TBL] [Abstract][Full Text] [Related]
9. [Infliximab for a girl with refractory pyoderma gangrenosum].
Nozawa T; Hara R; Kinoshita J; Sano F; Miyamae T; Imagawa T; Mori M; Hirokado M; Takahashi K; Inayama Y; Yokota S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):454-9. PubMed ID: 19122376
[TBL] [Abstract][Full Text] [Related]
10. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
Stichweh DS; Punaro M; Pascual V
Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
[TBL] [Abstract][Full Text] [Related]
11. Use of infliximab in pyoderma gangrenosum.
Hewitt D; Tait C
Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
[TBL] [Abstract][Full Text] [Related]
12. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of etanercept for postoperative pyoderma gangrenosum after infliximab serum sickness.
Ariane M; Bouaziz JD; de Masson A; Jachiet M; Bagot M; Lepelletier C
Dermatol Ther; 2019 Jan; 32(1):e12774. PubMed ID: 30341800
[TBL] [Abstract][Full Text] [Related]
14. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
Sapienza MS; Cohen S; Dimarino AJ
Dig Dis Sci; 2004 Sep; 49(9):1454-7. PubMed ID: 15481318
[TBL] [Abstract][Full Text] [Related]
16. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.
Grange F; Djilali-Bouzina F; Weiss AM; Polette A; Guillaume JC
Dermatology; 2002; 205(3):278-80. PubMed ID: 12399677
[TBL] [Abstract][Full Text] [Related]
18. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
Swale VJ; Saha M; Kapur N; Hoffbrand AV; Rustin MH
Clin Exp Dermatol; 2005 Mar; 30(2):134-6. PubMed ID: 15725238
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
Argüelles-Arias F; Castro-Laria L; Lobatón T; Aguas-Peris M; Rojas-Feria M; Barreiro-de Acosta M; Soto-Escribano P; Calvo-Moya M; Ginard-Vicens D; Chaparro-Sánchez M; Hernández-Durán M; Castro-Senosiain B; Fernández-Villaverde A; García-Sánchez V; Domínguez-Muñoz E; Caunedo-Álvarez A; Herrerías-Gutiérrez JM
Dig Dis Sci; 2013 Oct; 58(10):2949-54. PubMed ID: 23828140
[TBL] [Abstract][Full Text] [Related]
20. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
